Literature DB >> 33644032

Erythroblastic Island Macrophages Shape Normal Erythropoiesis and Drive Associated Disorders in Erythroid Hematopoietic Diseases.

Wei Li1, Rongqun Guo1, Yongping Song1, Zhongxing Jiang1.   

Abstract

Erythroblastic islands (EBIs), discovered more than 60 years ago, are specialized microenvironments for erythropoiesis. This island consists of a central macrophage with surrounding developing erythroid cells. EBI macrophages have received intense interest in the verifications of the supporting erythropoiesis hypothesis. Most of these investigations have focused on the identification and functional analyses of EBI macrophages, yielding significant progresses in identifying and isolating EBI macrophages, as well as verifying the potential roles of EBI macrophages in erythropoiesis. EBI macrophages express erythropoietin receptor (Epor) both in mouse and human, and Epo acts on both erythroid cells and EBI macrophages simultaneously in the niche, thereby promoting erythropoiesis. Impaired Epor signaling in splenic niche macrophages significantly inhibit the differentiation of stress erythroid progenitors. Moreover, accumulating evidence suggests that EBI macrophage dysfunction may lead to certain erythroid hematological disorders. In this review, the heterogeneity, identification, and functions of EBI macrophages during erythropoiesis under both steady-state and stress conditions are outlined. By reviewing the historical data, we discuss the influence of EBI macrophages on erythroid hematopoietic disorders and propose a new hypothesis that erythroid hematopoietic disorders are driven by EBI macrophages.
Copyright © 2021 Li, Guo, Song and Jiang.

Entities:  

Keywords:  EBI macrophages; EPOR; central macrophages; erythroid hematopoietic disorders; erythropoiesis; polycythemia vera; β-thalassemia

Year:  2021        PMID: 33644032      PMCID: PMC7907436          DOI: 10.3389/fcell.2020.613885

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  8 in total

1.  Isolation of Healthy F4/80+ Macrophages from Embryonic day E13.5 Mouse Fetal Liver Using Magnetic Nanoparticles for Single Cell Sequencing.

Authors:  Kaustav Mukherjee; James J Bieker
Journal:  Bio Protoc       Date:  2021-12-05

Review 2.  Natural killer cells: a promising immunotherapy for cancer.

Authors:  Junfeng Chu; Fengcai Gao; Meimei Yan; Shuang Zhao; Zheng Yan; Bian Shi; Yanyan Liu
Journal:  J Transl Med       Date:  2022-05-23       Impact factor: 8.440

3.  Differences in Steady-State Erythropoiesis in Different Mouse Bones and Postnatal Spleen.

Authors:  Vamsee D Myneni; Ildikó Szalayova; Eva Mezey
Journal:  Front Cell Dev Biol       Date:  2021-05-13

4.  GM-CSF impairs erythropoiesis by disrupting erythroblastic island formation via macrophages.

Authors:  Weijie Cao; Wenjuan Fan; Fang Wang; Yinyin Zhang; Guanghua Wu; Xiaojing Shi; Jian Xiang Shi; Fengcai Gao; Meimei Yan; Rong Guo; Yingmei Li; Wei Li; Chunyan Du; Zhongxing Jiang
Journal:  J Transl Med       Date:  2022-01-03       Impact factor: 5.531

Review 5.  Transcriptional Control of Gene Expression and the Heterogeneous Cellular Identity of Erythroblastic Island Macrophages.

Authors:  Kaustav Mukherjee; James J Bieker
Journal:  Front Genet       Date:  2021-11-22       Impact factor: 4.599

6.  SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.

Authors:  Hui Yang; Meimei Yan; Wei Li; Linping Xu
Journal:  J Transl Med       Date:  2022-03-22       Impact factor: 5.531

Review 7.  Targeting macrophages in hematological malignancies: recent advances and future directions.

Authors:  Wei Li; Fang Wang; Rongqun Guo; Zhilei Bian; Yongping Song
Journal:  J Hematol Oncol       Date:  2022-08-17       Impact factor: 23.168

8.  Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Linping Xu; Meimei Yan; Jianpeng Long; Mengmeng Liu; Hui Yang; Wei Li
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.